Trial Profile
A National, Multi-center, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Everolimus Combined With Enteric-coated Mycophenolate Sodium Compared to the Standard Treatment Combining Tacrolimus and Enteric-coated Mycophenolate Sodium in de Novo Liver Transplant Recipients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Basiliximab; Corticosteroids; Mycophenolate sodium; Tacrolimus
- Indications Liver transplant rejection
- Focus Pharmacodynamics; Registrational
- Acronyms SIMCER
- Sponsors Novartis Pharmaceuticals
- 30 Jan 2017 Results published in the American Journal of Transplantation
- 17 Apr 2016 Primary endpoint (Change From Baseline (Randomization) in Renal Function) has been met, according to the results presented at The International Liver Congress™ 2016
- 17 Apr 2016 Results presented at The International Liver Congress 2016